title: Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil.
abstract: The aim of this study was to evaluate the long term effects of the selective Ca2+-blocker verapamil on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. At the end of this clinical trial, plasma ANP levels increased by 16.14% despite the drop in blood pressure while left atrial and ventricular diameters remained unchanged. These findings indicate that the increase of ANP plasma levels is not the result of a mechanical load on the left cardiac chambers but the result of a pharmacological action. These observations also indicate that verapamil exerts part of its antihypertensive action by increasing ANP plasma levels.
authors: Departments of Second Cardiology, Medical School, Aristotle University of Thesssaloniki, Greece.
authors: B
authors: B
authors: Kokkas
authors: P
authors: P
authors: Kotridis
authors: M
authors: M
authors: Karamouzis
authors: I
authors: I
authors: Kanonidis
authors: G
authors: G
authors: Sakadamis
authors: G
authors: G
authors: Dadous
authors: S
authors: S
authors: Haritos
authors: P
authors: P
authors: Kyriakoui
authors: Theodossiadis
authors: P C
authors: PC
authors: Papadopoulos
authors: V
authors: V
authors: Mirtsou-Fidani
authors: C L
authors: CL
authors: Papadopoulos
mesh_terms: D000284:Administration, Oral; D000368:Aged; D009320:Atrial Natriuretic Factor / Q000097:blood*; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay; D014700:Verapamil / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D002121:Calcium Channel Blockers; D009320:Atrial Natriuretic Factor; D014700:Verapamil